Brinker Capital Inc. Buys 13,594 Shares of Becton Dickinson and Co (BDX)

Brinker Capital Inc. boosted its stake in Becton Dickinson and Co (NYSE:BDX) by 75.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,552 shares of the medical instruments supplier’s stock after purchasing an additional 13,594 shares during the period. Brinker Capital Inc.’s holdings in Becton Dickinson and were worth $7,109,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BDX. Oregon Public Employees Retirement Fund increased its holdings in Becton Dickinson and by 22,485.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 6,545,502 shares in the last quarter. Morgan Stanley increased its holdings in Becton Dickinson and by 133.0% in the 3rd quarter. Morgan Stanley now owns 2,771,269 shares of the medical instruments supplier’s stock valued at $723,303,000 after purchasing an additional 1,581,829 shares in the last quarter. FMR LLC increased its holdings in Becton Dickinson and by 8.0% in the 3rd quarter. FMR LLC now owns 17,354,031 shares of the medical instruments supplier’s stock valued at $4,529,401,000 after purchasing an additional 1,286,579 shares in the last quarter. Mackenzie Financial Corp increased its holdings in Becton Dickinson and by 27.7% in the 4th quarter. Mackenzie Financial Corp now owns 1,943,752 shares of the medical instruments supplier’s stock valued at $437,966,000 after purchasing an additional 421,825 shares in the last quarter. Finally, BlackRock Inc. increased its holdings in Becton Dickinson and by 1.9% in the 4th quarter. BlackRock Inc. now owns 19,384,283 shares of the medical instruments supplier’s stock valued at $4,367,665,000 after purchasing an additional 355,223 shares in the last quarter. Hedge funds and other institutional investors own 85.46% of the company’s stock.

Several brokerages recently issued reports on BDX. UBS Group began coverage on Becton Dickinson and in a report on Tuesday, November 27th. They issued a “neutral” rating and a $260.00 price target for the company. TheStreet upgraded Becton Dickinson and from a “c+” rating to an “a” rating in a report on Tuesday, February 5th. Zacks Investment Research downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Wednesday, February 6th. Piper Jaffray Companies increased their price target on Becton Dickinson and to $274.00 and gave the company an “overweight” rating in a report on Tuesday, February 5th. Finally, Deutsche Bank initiated coverage on Becton Dickinson and in a report on Thursday, December 6th. They issued a “buy” rating and a $280.00 price target for the company. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Becton Dickinson and currently has a consensus rating of “Buy” and a consensus target price of $253.55.

In related news, CEO Vincent A. Forlenza sold 3,123 shares of Becton Dickinson and stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $255.03, for a total value of $796,458.69. Following the completion of the transaction, the chief executive officer now directly owns 215,372 shares in the company, valued at $54,926,321.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Vincent A. Forlenza sold 11,340 shares of Becton Dickinson and stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $250.40, for a total value of $2,839,536.00. Following the completion of the transaction, the chief executive officer now owns 227,250 shares of the company’s stock, valued at $56,903,400. The disclosure for this sale can be found here. Insiders have sold 19,271 shares of company stock valued at $4,862,179 over the last 90 days. Insiders own 0.12% of the company’s stock.

Shares of Becton Dickinson and stock opened at $253.92 on Friday. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.97 and a quick ratio of 0.62. The stock has a market cap of $68.32 billion, a PE ratio of 23.06, a price-to-earnings-growth ratio of 1.76 and a beta of 1.21. Becton Dickinson and Co has a 1-year low of $208.62 and a 1-year high of $265.87.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.58 by $0.12. The company had revenue of $4.16 billion during the quarter, compared to the consensus estimate of $4.10 billion. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The company’s revenue was up 35.1% on a year-over-year basis. During the same period last year, the firm earned $2.48 earnings per share. On average, analysts predict that Becton Dickinson and Co will post 12.1 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 29th. Stockholders of record on Friday, March 8th will be paid a dividend of $0.77 per share. The ex-dividend date is Thursday, March 7th. This represents a $3.08 annualized dividend and a dividend yield of 1.21%. Becton Dickinson and’s dividend payout ratio is presently 27.97%.

COPYRIGHT VIOLATION NOTICE: “Brinker Capital Inc. Buys 13,594 Shares of Becton Dickinson and Co (BDX)” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2019/03/17/brinker-capital-inc-buys-13594-shares-of-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: Momentum Investing

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply